“
“Objective-To examine the association between liver fat content and very low-density selleckchem lipoprotein (VLDL)-apolipoprotein (apo) B-100 kinetics and the corresponding responses to weight loss in obese subjects.\n\nMethods and Results-VLDL-apoB-100 kinetics were assessed using stable isotope tracers, and the fat content of the liver and abdomen was determined by magnetic resonance techniques in 25 obese subjects. In univariate analysis, liver fat content was significantly (P < 0.05 in all) associated with body mass index (r = 0.65), visceral fat area (r = 0.45), triglycerides (r = 0.40), homeostasis model assessment score (r = 0.40), VLDL-apoB-100 concentrations (r = 0.44),

and secretion rate (r = 0.45). However, liver fat content was not associated with plasma concentrations of retinol-binding protein 4, fetuin A, adiponectin, interleukin-6, and tumor necrosis factor-alpha. Of these 25 subjects, 9 diagnosed as having

nonalcoholic fatty liver disease (which is highly prevalent in obese individuals and strongly associated with dyslipidemia) underwent a weight loss program. The low-fat diet achieved significant reduction in body weight, body mass index, liver fat, visceral and subcutaneous https://www.selleckchem.com/products/pexidartinib-plx3397.html fat areas, homeostasis model assessment score, triglycerides, VLDL-apoB-100 concentrations, and VLDL-apoB-100 secretion rate. The percentage reduction of liver fat with weight loss was significantly associated with the corresponding decreases in VLDL-apoB-100 secretion (r = 0.67) and visceral fat (r = 0.84).\n\nConclusion-In patients with obesity, hepatic steatosis increases VLDL-apoB-100 Selisistat secretion. Weight loss can help reduce this abnormality. (Arterioscler Thromb Vasc Biol. 2010;30:1043-1050.)”
“Benzotriazole derivatives have been shown to be able to induce growth inhibition in cancer cells. In the present study, we synthesized bioactive

compound, 3-(1H-benzo [d] [1,2,3] triazol-1-yl)-1-(4-methoxyphenyl)-1-oxopropan-2-yl benzoate (BmOB), which is a novel benzotriazole derivative. BmOB displayed anti-proliferative effects on several human tumor cell lines. Human hepatocarcinoma BEL-7402 cell line was selected as a model to illustrate BmOB’s inhibition effect and its potential mechanism, since it was the highest susceptible cell line to BmOB. It was shown that treatment with BmOB resulted in generation of reactive oxygen species, disruption of mitochondrial membrane potential (Delta psi m), and cell death in BEL-7402 cells. BmOB induced cytotoxicity could be prevented by antioxidant vitamin C and mitochondrial permeability transition inhibitor cyclosporine A. cyclosporine A could also protect the BmOB induced collapse of Delta psi m in BEL7402 cells, while vitamin C did not show similar effects. The results suggest that BmOB could inhibit BEL-7402 cell proliferation, and the cell death may occur through the modulation of mitochondrial functions regulated by reactive oxygen species.